Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 113

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 113
---
 liabilities

    25,402

    22,291

    Accrued payroll and employee liabilities

    9,554

    9,224

    Other accrued liabilities

    41,755

    41,855

    Current lease liabilities

    3,037

    3,075

    Total current liabilities

    91,457

    79,685

    Non-current lease liabilities

    —

    2,800

    Non-current notes payable, net

    25,026

    24,263

    Non-current convertible notes payable, net

    149,700

    149,490

    Other non-current liabilities

    615

    241

    Total liabilities

    266,798

    256,479

    Commitments and contingencies (see Note 6)

    Stockholders’ deficit:

    Common stock, $0.01 par value: 400,000,000 shares authorized; 152,127,878 shares issued and outstanding at December 31, 2024 and 225,000,000 shares authorized; 150,285,044 shares issued and outstanding at December 31, 2023

    1,521

    1,503

    Additional paid-in capital

    1,884,409

    1,870,525

    Accumulated other comprehensive income

    13

    13

    Accumulated deficit

    (1,919,594
    )

    (1,906,014
    )

    Total stockholders’ deficit

    (33,651
    )

    (33,973
    )

    Total liabilities and stockholders’ deficit
     
    $
    233,147

    $
    222,506

See accompanying Notes to Consolidated Financial Statements.

74

HERON THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share amounts)

    Years Ended December 31,

    2024

    2023

    2022

    Revenues:

    Net product sales
     
    $
    144,285

    $
    127,044

    $
    107,672

    Cost of product sales

    38,648

    65,105

    54,874